Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Xiangrui Meng(Xuzhou Medical College), Feng Wang(First Affiliated Hospital of Zhengzhou University), Jianxiang Xing(First Affiliated Hospital of Zhengzhou University), Zhiquan Luo(Xinyang Central Hospital), Zhiguo Hou(Jiangsu Hengrui Medicine (China)), Wenchang Liang(Anyang Tumor Hospital), Ping Lu(First Affiliated Hospital of Xinxiang Medical University), Wenkang Wang(ZheJiang Institute For Food and Drug Control), Taiying Lu(First Affiliated Hospital of Zhengzhou University), Guozhong Jiang(First Affiliated Hospital of Zhengzhou University), Wenqing Zhu(Shanghai University), Hong Zong(Zhengzhou University), Lu Yao(Tianjin Medical University Cancer Institute and Hospital), Yue Zhou(First Affiliated Hospital of Zhengzhou University), Bing‐Hua Jiang(Thomas Jefferson University), Zhengzheng Shan(First Affiliated Hospital of Zhengzhou University), Han Wu(Affiliated Hospital of Nantong University), Lulu Guan(First Affiliated Hospital of Zhengzhou University), Dao Xin(First Affiliated Hospital of Zhengzhou University), Min Seok Song(Seoul National University), Min Zhang(Shanxi Medical University), Liuzhong Yang(First Affiliated Hospital of Xinxiang Medical University), Junsheng Wang(Anyang Tumor Hospital), Shenglei Li(First Affiliated Hospital of Zhengzhou University), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Tao Wu(Anyang Tumor Hospital), Peng Cheng(Nanyang Medical College), Yinghua Ji(First Affiliated Hospital of Xinxiang Medical University), Yanke Li(First Affiliated Hospital of Zhengzhou University), Jin Xia(Anyang Tumor Hospital), Xi Luo(First Affiliated Hospital of Zhengzhou University), Aijia Li(Zhengzhou University), Lijie Song(First Affiliated Hospital of Zhengzhou University), Yanzhen Guo(First Affiliated Hospital of Henan University of Science and Technology), Rongrong Zheng(Jiangsu Hengrui Medicine (China)), Yun Jia(Sinovac Biotech), Yonggui Hong(Anyang Tumor Hospital), Jingwen Chu(First Affiliated Hospital of Zhengzhou University), Feng Zhao(Jiangsu Hengrui Medicine (China)), Mingyue Wang(First Affiliated Hospital of Zhengzhou University), Siyuan Xing(First Affiliated Hospital of Zhengzhou University)
Cited by 18
Related Papers
Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation
|JMIR Medical Informatics|2019|558
Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer
|Clinical Cancer Research|2011|338
Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy
|Molecular Cell|2017|282